Keywords: biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: VEGF; Vascular Endothelial Growth Factor; MMP; Matrixmetalloproteinases; uPAR; UrokinasePlasminogen Activator Receptor; Ang-1; Angiotensin-1; TGF-β; Transforming Growth Factor-β; VEGFR; Vascular Endothelial Growth Factor Receptor; TKI; Tyrosine Kinase I
Keywords: Tyrosine kinase inhibitors; Drug transporter; Drug interaction; Therapeutic drug monitoring; Skin disorders; ADR; Adverse drug reaction; AUC; Area under the curve; BBB; Blood-brain barrier; BCRP/ABCG2; Breast cancer resistance protein; CNS; Central nerv
Keywords: cancer therapy; chemotherapy; cutaneous reactions; drug hypersensitivity; rash; target drugs; EGFR; epidermal growth factor receptor; EGFRI; epidermal growth factor receptor inhibitor; HFSR; hand-foot skin reaction; IRAE; immune-related adverse event; M
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues
Keywords: Apoptosis; Drug safety; Imatinib; Narrow Therapeutic Index Drug (NTID); Receptor tyrosine kinase (RTK); Sunitinib; Toxicity; Tyrosine kinase inhibitor (TKI); Cell viability; ALL; acute lymphoblastic leukemia; AUC; area under the curve; b.i.d.; twice daily
Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management
Keywords: chemotherapy complications; chemotherapy nail complications; hand-foot skin reaction; hand-foot syndrome; molecular targeted therapy complications; palmoplantar erythrodysesthesia; FU; fluorouracil; GVHD; graft-versus-host disease; HFS; hand-foot syndrome
Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science
Keywords: AASLD; American Association for the Study of Liver Diseases; AE; adverse event; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; CR; complete response; DCR; disease control rate; DEB; doxorubicin-eluting bead; ECOG; Eastern Cooperative Oncolo
Research ArticlePhase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
Keywords: Sorafenib; Tegafur/uracil; Metronomic chemotherapy; Hepatocellular carcinoma; HCC; hepatocellular carcinoma; PFS; progression-free survival; C.I.; confidence interval; RECIST; response evaluation criteria in solid tumors; HFSR; hand-foot skin reaction; VE